TSXV:VER.H - Post by User
Post by
herbaciouson Apr 04, 2011 9:50am
139 Views
Post# 18380878
THE BUSINESS END
THE BUSINESS ENDVerisante has both the TECHNOLOGY AND BUSINESS end!
verisante handles very little in house and instead mostly in-licence s and out sources
this keeps fixed costs low, migates risk and maximizes expertise of major functions.
The company"s low cost base ,razor blade business model and the opportunity afforded by the ex-US markets alone should allow Verisante to turn cash flow positive in relatively short order.
Verisante should post positive earnings by 2013. And while US clinical trials (expected in 2012) will require capital it will be manageable from a combination of operating cash flow from sales to ex-US markets and external financing.
do your own due diligence
herb